A group of nursing students are reviewing the different types of congenital heart disease in infants
The students demonstrate a need for additional review when they identify which of the following as an example of increased pulmonary blood flow (left-to-right shunting)? A) Atrial septal defect
B) Tetralogy of Fallot
C) Ventricular septal defect
D) Patent ductus arteriosus
B
Feedback:
Tetralogy of Fallot is a congenital heart condition that results from decreased, not increased, pulmonary blood flow. Atrial septal defect, ventricular septal defect, and patent ductus arteriosus are heart conditions that involve increased blood flow from higher pressure (left side of heart) to lower pressure (right side of heart), resulting in left-to-right shunting.
You might also like to view...
Ways to reduce risk of infection to yourself and others include:
A) Not going into the client's room B) Wearing gloves whenever you go into a client's room C) Placing all clients in isolation rooms D) Good handwashing practices
Which of the following sexual characteristics occur at the onset of puberty? Select all that apply
a. Absence of pubic hair d. Increase in estrogen production b. Breast enlargement e. Increased urination c. Contour changes of hips and abdomen f. Elevated testosterone levels
In planning the care of a patient who has hyperthyroidism, the nurse has identified the nursing diagnosis of altered nutrition: less than body requirements. What intervention is the best response to this diagnosis?
A) Arrange for the patient to be assessed for the possible use of enteral nutrition. B) Provide the patient with a low-fat, high-protein diet. C) Provide several small meals each day for the patient. D) Teach the patient to eat each meal slowly and methodically.
It is determined that a patient has poor cardiac contractility. The nurse would anticipate administering which type of drugs to improve contractility?
1. Cardiac glycosides 2. Loop diuretics 3. Sympathomimetic agents 4. Phosphodiesterase inhibitors 5. Angiotension-converting enzyme (ACE) inhibitors